DE3490749T1 - Derivate von ll-Desoxy-17α-oxykortikosteron - Google Patents
Derivate von ll-Desoxy-17α-oxykortikosteronInfo
- Publication number
- DE3490749T1 DE3490749T1 DE19843490749 DE3490749T DE3490749T1 DE 3490749 T1 DE3490749 T1 DE 3490749T1 DE 19843490749 DE19843490749 DE 19843490749 DE 3490749 T DE3490749 T DE 3490749T DE 3490749 T1 DE3490749 T1 DE 3490749T1
- Authority
- DE
- Germany
- Prior art keywords
- deoxy
- chloroethane
- oxy
- tumors
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 description 42
- 150000001875 compounds Chemical class 0.000 description 27
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 24
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 22
- -1 amino- Chemical class 0.000 description 18
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 238000011282 treatment Methods 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 8
- 230000002269 spontaneous effect Effects 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- UIHVAXRVVJJTHU-UHFFFAOYSA-N 2-[bis(2-chloroethyl)amino]acetic acid Chemical group OC(=O)CN(CCCl)CCCl UIHVAXRVVJJTHU-UHFFFAOYSA-N 0.000 description 6
- 150000008064 anhydrides Chemical class 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000003862 glucocorticoid Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 230000002152 alkylating effect Effects 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 210000005075 mammary gland Anatomy 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000000118 anti-neoplastic effect Effects 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical class C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000003054 hormonal effect Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 229940037128 systemic glucocorticoids Drugs 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 3
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- RTEXIPZMMDUXMR-UHFFFAOYSA-N benzene;ethyl acetate Chemical compound CCOC(C)=O.C1=CC=CC=C1 RTEXIPZMMDUXMR-UHFFFAOYSA-N 0.000 description 3
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 3
- MDHYEMXUFSJLGV-UHFFFAOYSA-N beta-phenethyl acetate Natural products CC(=O)OCCC1=CC=CC=C1 MDHYEMXUFSJLGV-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000011287 therapeutic dose Methods 0.000 description 3
- UQFHJDVUQSAVOQ-UHFFFAOYSA-N (2-aminophenyl) acetate Chemical compound CC(=O)OC1=CC=CC=C1N UQFHJDVUQSAVOQ-UHFFFAOYSA-N 0.000 description 2
- DIIIISSCIXVANO-UHFFFAOYSA-N 1,2-Dimethylhydrazine Chemical compound CNNC DIIIISSCIXVANO-UHFFFAOYSA-N 0.000 description 2
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 2
- UBXUDSPYIGPGGP-UHFFFAOYSA-N 2-azaniumyl-2-phenylbutanoate Chemical compound CCC(N)(C(O)=O)C1=CC=CC=C1 UBXUDSPYIGPGGP-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- SGDBTWWWUNNDEQ-UHFFFAOYSA-N Merphalan Chemical compound OC(=O)C(N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000003470 adrenal cortex hormone Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 108091007930 cytoplasmic receptors Proteins 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 229960003750 ethyl chloride Drugs 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 229960004694 prednimustine Drugs 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 229950004157 sarcolysin Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HKDXWGXBFROANX-UHFFFAOYSA-N (2-aminophenyl) butanoate Chemical compound CCCC(=O)OC1=CC=CC=C1N HKDXWGXBFROANX-UHFFFAOYSA-N 0.000 description 1
- ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 208000036652 Adenocarcinoma of the small intestine Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 241000766026 Coregonus nasus Species 0.000 description 1
- VFZRZRDOXPRTSC-UHFFFAOYSA-N DMBA Natural products COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 206010061188 Haematotoxicity Diseases 0.000 description 1
- 208000007093 Leukemia L1210 Diseases 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- QVQAEPOXJMGOON-UHFFFAOYSA-N carbamic acid;chloroethane Chemical compound CCCl.NC(O)=O QVQAEPOXJMGOON-UHFFFAOYSA-N 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- ZESRJSPZRDMNHY-UHFFFAOYSA-N de-oxy corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 ZESRJSPZRDMNHY-UHFFFAOYSA-N 0.000 description 1
- 229940119740 deoxycorticosterone Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 231100000226 haematotoxicity Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 231100000508 hormonal effect Toxicity 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachlorophenol Chemical compound OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- 229940037129 plain mineralocorticoids for systemic use Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 206010073373 small intestine adenocarcinoma Diseases 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/SU1984/000043 WO1986000908A1 (fr) | 1984-07-31 | 1984-07-31 | DERIVES DE 11-DESOXY-17alpha-OXYCORTICOSTERONE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE3490749T1 true DE3490749T1 (de) | 1986-08-07 |
Family
ID=21616860
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19843490749 Pending DE3490749T1 (de) | 1984-07-31 | 1984-07-31 | Derivate von ll-Desoxy-17α-oxykortikosteron |
| DE19843490749 Expired DE3490749C2 (de) | 1984-07-31 | 1984-07-31 | 11-Desoxy-17alpha-hydroxycorticosteronester |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19843490749 Expired DE3490749C2 (de) | 1984-07-31 | 1984-07-31 | 11-Desoxy-17alpha-hydroxycorticosteronester |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4810701A (enExample) |
| JP (1) | JPH01500111A (enExample) |
| CH (1) | CH666044A5 (enExample) |
| DE (2) | DE3490749T1 (enExample) |
| FI (1) | FI80048C (enExample) |
| GB (1) | GB2176189B (enExample) |
| SE (1) | SE448166B (enExample) |
| WO (1) | WO1986000908A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4933332A (en) * | 1986-03-21 | 1990-06-12 | Kurdjumova Kira N | 11-desoxy-17-α-hydroxycorticosterone derivatives |
| US5483697A (en) * | 1989-05-22 | 1996-01-16 | Board Of Regents The University Of Texas | Multilayer protective coverings with a sealing solution |
| AP141A (en) * | 1990-04-25 | 1991-08-25 | Richter Gedeon Vegyeszet | Novel steroid doils. |
| WO1992018089A2 (en) * | 1991-04-09 | 1992-10-29 | The Upjohn Company | Use of steroidal and non-steroidal amines to sensitize multidrug-resistant cells |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1793461A1 (de) * | 1968-09-20 | 1971-07-01 | Hoechst Ag | 21-(Cyclobutyl-carbonsaeure)-ester von Steroidderivaten und Verfahren zu ihrer Herstellung |
| GB1272841A (en) * | 1969-01-23 | 1972-05-03 | Leo Ab | New corticoid steroid compounds of cytostatic interest |
| GB1558472A (en) * | 1976-01-22 | 1980-01-03 | Leo Ab | 17-esters of 17- hydroxy gestogens |
| US4261910A (en) * | 1978-08-14 | 1981-04-14 | Kureha Kagaku Kogyo Kabushiki Kaisha | Process for the preparation of Chlorambucil derivatives |
-
1984
- 1984-07-31 US US06/852,459 patent/US4810701A/en not_active Expired - Fee Related
- 1984-07-31 DE DE19843490749 patent/DE3490749T1/de active Pending
- 1984-07-31 GB GB08606415A patent/GB2176189B/en not_active Expired
- 1984-07-31 CH CH1341/86A patent/CH666044A5/de not_active IP Right Cessation
- 1984-07-31 JP JP59503853A patent/JPH01500111A/ja active Granted
- 1984-07-31 WO PCT/SU1984/000043 patent/WO1986000908A1/ru not_active Ceased
- 1984-07-31 DE DE19843490749 patent/DE3490749C2/de not_active Expired
-
1986
- 1986-03-21 SE SE8601344A patent/SE448166B/sv not_active IP Right Cessation
- 1986-03-26 FI FI861325A patent/FI80048C/fi not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CH666044A5 (de) | 1988-06-30 |
| WO1986000908A1 (fr) | 1986-02-13 |
| SE8601344D0 (sv) | 1986-03-21 |
| GB2176189B (en) | 1988-03-02 |
| FI861325L (fi) | 1986-03-26 |
| JPH01500111A (ja) | 1989-01-19 |
| FI861325A0 (fi) | 1986-03-26 |
| GB8606415D0 (en) | 1986-04-23 |
| DE3490749C2 (de) | 1989-12-28 |
| JPH0124160B2 (enExample) | 1989-05-10 |
| US4810701A (en) | 1989-03-07 |
| SE8601344L (sv) | 1986-03-21 |
| SE448166B (sv) | 1987-01-26 |
| FI80048C (fi) | 1990-04-10 |
| FI80048B (fi) | 1989-12-29 |
| GB2176189A (en) | 1986-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69132048T2 (de) | Verwendung von Steroiden zur Inhibierung von Angiogenesis | |
| EP0000742B1 (de) | Corticoid-17-Alkylcarbonate und Verfahren zu deren Herstellung und diese enthaltende Mittel | |
| DE3027039C2 (de) | Arzneimittel auf Corticosteroid-Basis | |
| WO2001045678A2 (de) | Arzneimittel, verfahren zu dessen herstellung und dessen verwendung | |
| EP1594885A1 (de) | Medikament zur wachstumsinhibierung von tumoren | |
| DE4025342A1 (de) | In 17-stellung substituierte corticoid-17-alkylcarbonate, verfahren zu deren herstellung und diese enthaltende arzneimittel | |
| DE2812164A1 (de) | Verwendung von wirkstoffvorlaeufern bei der bekaempfung bzw. behandlung von proliferativen hauterkrankungen | |
| DE3490749T1 (de) | Derivate von ll-Desoxy-17&alpha;-oxykortikosteron | |
| DE2222491C3 (de) | Steroid-21-salpetersäureester der Pregnanreihe, solche enthaltende Arzneimittel und Verfahren zur Herstellung derselben | |
| DE1618065C3 (de) | 21-Oxo-23-desoxo-cardenoIide, Verfahren zu deren Herstellung und daraus hergestellte Arzneimittel | |
| DE3336292C2 (enExample) | ||
| DE2501091A1 (de) | 17-alpha-aethinyl-(5-alpha)-2-androsten-17-beta-ol und sein 17-beta-acetat, verfahren zu ihrer herstellung und ihre therapeutische verwendung | |
| EP0757055B1 (de) | Glykoside, deren zuckerfreie Abbauprodukte und Derivate derselben | |
| DE2055895C2 (de) | Verfahren zur Herstellung von 3-Keto-&Delta;&uarr;4&uarr;-6-methylen-steroiden | |
| DE3149528A1 (de) | Mittel auf der grundlage eines in 10-stellung substituierten 1,8-dihydro-9-anthrons zur behandlung von psoriasis | |
| DE2431916B2 (de) | Acetylthio- und/oder Mercaptogruppen enthaltende 17alpha-(2'-Carboxyäthyl)-17beta-ol-lacton-Steroide, diese enthaltende Arzneimittel, Verfahren zur Herstellung derselben sowie entsprechende Brom enthaltende Steroide als Zwischenprodukte | |
| EP1845963A2 (de) | Isolierung von n-butylbenzolsulfonamid, synthese von benzolsulfonamid-derivaten sowie verwendung von n-butylbenzolsulfonamid und benzolsulfonamid-derivaten zur behandlung der benignen prostatahyperplasie und/oder des prostatakarzinoms | |
| DE1620606A1 (de) | Verfahren zur Herstellung von Aminoacylcyetosamin derivaten | |
| DE19707854A1 (de) | Neue Cyclopeptide, deren Herstellung und Verwendung | |
| DE2601367C3 (de) | Steroid [(1-Benzyl-1H-indazol-3-yl)-oxy]-essigsäure und Verfahren zu ihrer Herstellung | |
| DE1618917C3 (de) | 6 alpha, 21-Difluorsteroide sowie Verfahren zu deren Herstellung | |
| DE1807585C3 (de) | 14,15beta-Epoxycardenolide, Verfahren zu deren Herstellung und diese enthaltende Mittel | |
| DE1793694C3 (de) | Helveticosidderivate | |
| EP0030331B1 (de) | Neue C-3-verzweigte Cardenolid-glykoside, ihre Herstellung und Verwendung | |
| DE2022308C3 (de) | Verfahren zur Herstellung von 2 alpha , 3 alpha -Epithio-5 alpha steroiden |